Loading…
Reported covered position: Sen. Olympia Snowe Senate Campaign 7/94-11/94
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · third_quarter · Q3
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Implementation of P.L. 117-169 provisions related to Medicare prescription drugs; Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines; Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program.
Source: Senate LDA
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (H.R. 830/S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
PSA Screening for HIM Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Consolidated Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
NOPAIN Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
HELP Copays Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
New Era of Preventing End-Stage Kidney Disease Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Food and Drug Amendments of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
United States Innovation and Competition Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
PREVENT Pandemics Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
FDASLA Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
FDASLA Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
FDASLA Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
A resolution supporting the goals and ideals of World Sickle Cell Awareness Day.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Inflation Reduction Act of 2022
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes.
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Lower Costs, More Cures Act of 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
Consolidated Appropriations Act, 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Consolidated Appropriations Act, 2021
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Fairness in Orphan Drug Exclusivity Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Fairness in Orphan Drug Exclusivity Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Families First Coronavirus Response Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Families First Coronavirus Response Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
CARES Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Prescription Drug Pricing Reduction Act of 2019
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
Prescription Drug Pricing Reduction Act of 2019
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Prescription Drug Pricing Reduction Act of 2019
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
Prescription Drug STAR Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Prescription Drug STAR Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "FAIR Drug Pricing Act," and S. 1895: "Lower Health Care Costs Act").
Prescription Drug STAR Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
More Efficient Tools to Realize Information for Consumers Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
More Efficient Tools to Realize Information for Consumers Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "FAIR Drug Pricing Act," and S. 1895: "Lower Health Care Costs Act").
More Efficient Tools to Realize Information for Consumers Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Elijah E. Cummings Lower Drug Costs Now Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
Lower Health Care Costs Act
Client: VERTEX PHARMACEUTICALS INCORPORATED · Firm: VERTEX PHARMACEUTICALS INCORPORATED
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · second_quarter · Q2
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2023 · first_quarter · Q1
Issues related to corporate and international tax policy and research and development tax credits.
Issues related to funding for the Food and Drug Administration - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; General education about policies to improve outcomes for patients with APOL-1 kidney disease.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · fourth_quarter · Q4
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; S .586/H.R.3259 - NOPAIN Act, H.R.2617 - Consolidated Appropriations Act, 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · third_quarter · Q3
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
Issues related to FDA regulatory drug review and approval in H.R. 6833, HR 7667 Food and Drug Amendments of 2022, S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · second_quarter · Q2
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - "Build Back Better Act."
Issues related to funding for the Food and Drug Administration; S. 2599/H.R. 4356 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2022; Implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2022 · first_quarter · Q1
General education about FDA approval policies and NIH research activities. Policies related to the reauthorization of the Prescription Drug User Fee Act. Policies related to the FDA in S. 1260, "US Innovation and Competition Act," and HR 4521, "America COMPETES Act." Issues related to platform technologies and other FDA-related provisions in S. 3799, "PREVENT Pandemics Act."
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · third_quarter · Q3
Issues related to corporate and international tax policy and research and development tax credits (no specific bills). Issues related to the Orphan Drug Tax Credit. Issues related to corporate and international tax policy in HR 5376, "Build Back Better Act."
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act"; H Res 494, "Expressing support for the designation of September 2021 as "Sickle Cell Disease Awareness Month"; and, H Res 495, "Calling for sickle cell trait research, surveillance, and public education and awareness, and for other purposes."
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2021 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to the development and application of gene and cell therapies (no specific bills); Issues related to health care cost and price transparency (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to corporate tax law and international tax policies (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · fourth_quarter · 4A
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · fourth_quarter · Q4
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response and extension of health programs (H.R. 133, "Consolidated Appropriations Act, 2021").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act"); Issues related to Administration actions on pharmaceutical pricing (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · second_quarter · Q2
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act" and HR 4712: "Fairness in Orphan Drug Exclusivity Act.").
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act"; HR 6201: "Families First Coronavirus Response Act", and HR 6074: "Coronavirus Preparedness and Response Supplemental Appropriations Act").
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2020 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (no specific bills); Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · fourth_quarter · Q4
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "More Efficient Tools to Realize Information for Consumers Act", and S. 1895: "Lower Health Care Costs Act").
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act", S. 2543: "Prescription Drug Pricing Reduction Act," and HR 3: "Lower Drug Costs Now Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: More Efficient Tools to Realize Information for Consumers Act, and S. 1895: "Lower Health Care Costs Act").
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (S. 1895: "Lower Health Care Costs Act"); Issues related to health care cost and price transparency (HR 2113: "Prescription Drug STAR Act," HR 2296: "FAIR Drug Pricing Act," and S. 1895: "Lower Health Care Costs Act").
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2019 · first_quarter · Q1
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills). Issues related to health care cost and price transparency (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · first_quarter · 1A
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing (no specific bills).
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2018 · first_quarter · Q1
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills).
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to H.R. 1, The Tax Cuts & Jobs Act, including the Orphan Drug Tax Credit, corporate tax rate, foreign earnings rate, and employee benefits.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · third_quarter · Q3
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 3921, the HEALTHY KIDS ACT, and S. 1827, the KIDS Act, to reauthorize the State Children's Health Insurance Program.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430 - FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · second_quarter · Q2
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to rare disease and orphan disease patient access in Medicaid.
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 2430, the FDA Reauthorization Act of 2017, provisions related to extending user-free programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2017 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 1628 - American Health Care Act of 2017, issues related to the repeal of the Affordable Care Act (ACA); H.R. 1223 - OPEN Act, provisions related to amending the Federal Food, Drug, and Cosmetic Act to authorize extension of exclusivity periods for certain drugs approved for a new indication for a rare disease or condition.
Issues related to rare disease and orphan disease patient access in Medicaid.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · fourth_quarter · Q4
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · third_quarter · Q3
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · second_quarter · Q2
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016. S. Res. 476, Designating the month of May 2016 as "Cystic Fibrosis Awareness Month."
Issues related to the Orphan Drug Tax Credit (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2016 · first_quarter · Q1
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015; S.2713 Advancing Precision Medicine Act of 2016.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · fourth_quarter · Q4
H.R. 9 Innovation Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills);S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · third_quarter · Q3
H.R. 9 Innovation Act (all provisions)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Issues related to the Orphan Drug Tax Credit (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · second_quarter · Q2
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2015 · first_quarter · Q1
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to the "21st Century Cures Act" Discussion Draft (no specific bills); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills).
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · fourth_quarter · Q4
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions)
Issues related to the Orphan Drug Tax Credit (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · third_quarter · Q3
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions); Issues related to the reauthorization of the Medicaid State Children's Health Insurance Program (no specific bills)
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · second_quarter · Q2
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions).
Issues related to regulatory reforms and drug development under the Energy & Commerce Committee's 21st Century Cures initiative (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2014 · first_quarter · Q1
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · fourth_quarter · Q4
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
S. 1720 Patent Transparency and Improvements Act of 2013 (all provisions); H.R. 3309 Innovation Act (all provisions)
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · third_quarter · Q3
H.R. 2827/S. 1365 The Part D Beneficiary Appeals Fairness Act (all provisions)
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions); H.R. 2725 FDA Safety Over Sequestration (SOS) Act (all provisions); H.R. 3204 Drug Quality and Security Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · second_quarter · Q2
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2013 · first_quarter · Q1
Issues related to raising awareness of Hepatitis C (no specific bills); Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 460 The Patients' Access to Treatments Act of 2013 (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2012 · fourth_quarter · Q4
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions.
FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013 (S.3295), provisions related to viral hepatitis funding.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2012 · third_quarter · Q3
FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013 (S.3295), provisions related to viral hepatitis funding.
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2012 · second_quarter · Q2
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; The Food and Drug Administration Safety and Innovation Act (S.3187), all provisions; To amend chapter V of the Federal Food, Drug, and Cosmetic Act to expedite the development and review of breakthrough therapies (H.R.5334), all provisions; The FAST Act (H.R.4132), all provisions; The Food and Drug Administration Reform Act of 2012 (H.R.5651), all provisions.
FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, BARDA funding, and funding the Strategic National Stockpile; The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013 (S.3295), provisions related to viral hepatitis funding, BARDA funding, and funding the Strategic National Stockpile.
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2012 · first_quarter · Q1
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1809), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions; (cont'd next page) Expanding and Promoting Expertise in Review of Rare Treatments Act of 2012 (H.R.4156 , S.2281), all provisions; Transforming the Regulatory Environment to Accelerate Access to Treatments (S.2113), provisions; The Unlocking Lifesaving Treatments for Rare-Diseases Act (H.R.3737), all provisions; Issues related to the 2012 Prescription Drug User Fee Act Reauthorization Discussion Draft, all provisions
FY 2013 Labor/HHS/Education Draft, provisions related to viral hepatitis funding, BARDA funding, and funding the Strategic National Stockpile.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2011 · fourth_quarter · Q4
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis Testing Act of 2011 (H.R. 3381, S. 1089), all provisions; Pandemic and All-Hazards Preparedness Reauthorization Act of 2011 (H.R. 2405, S. 1855), all provisions.
FY 2012 Labor/HHS/Education (H.R. 3070 and S. 1599), provisions related to viral hepatitis funding.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2011 · third_quarter · Q3
FY 2012 Labor/HHS/Education Appropriations (H.R. 3070 and S. 1599), provisions related to viral hepatitis funding
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; H.R. 2405 Pandemic and All-Hazards Preparedness Reauthorization Act of 2011, all provisions.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2011 · second_quarter · Q2
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2012 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; S 23/HR 1249 America Invents Act, provisions related to supplemental examination, fee diversion, and first inventor to file.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2011 · first_quarter · Q1
Issues related to raising awareness of Hepatitis C (no specific bills); Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2011 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; S 23/HR 1249 America Invents Act, general discussions.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
VERTEX PHARMACEUTICALS INCORPORATED via VERTEX PHARMACEUTICALS INCORPORATED
2010 · fourth_quarter · Q4
Issues related to raising awareness of Hepatitis C (no specific bills); HR 3293, H.R. 3288: FY 2010 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding; H.R.3974: Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009; all provisions; S. 3711, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2010, all provisions; FY 2011 Labor/HHS/Education Appropriations, provisions related to viral hepatitis funding.
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Issues related to FDA regulatory pathways for pharmaceuticals; Issues related to pharmaceutical pricing, health care cost and price transparency: H.R. 3 - "Elijah E. Cummings Lower Drug Costs Now Act"; H.R. 19 - "Lower Costs, More Cures Act"; S. 2164 - "Lower Costs, More Cures Act."; Issues related to health care and prescription drug pricing in H.R. 5376 - "Build Back Better Act"; H.R. 5801 - HELP Copays Act. HR 7506 - "New Era of Preventing End-Stage Kidney Disease Act." S. Res 683 and H.R. 1176 - Recognizing World Sickle Cell Awareness Day.
General education about FDA approval policies and NIH research activities; Policies related to the reauthorization of the Prescription Drug User Fee Act (H.R. 7667 and S. 4348); Policies related to the FDA in S. 1260 - "US Innovation and Competition Act" and H.R. 4521 - "America COMPETES Act"; Issues related to platform technologies and other FDA-related provisions in S. 3799 - "PREVENT Pandemics Act."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to pharmaceutical pricing, health care cost and price transparency: HR 3, "Elijah E. Cummings Lower Drug Costs Now Act"; HR 19, "Lower Costs, More Cures Act"; S 2164, "Lower Costs, More Cures Act." Issues related to health care and prescription drug pricing in HR 5376, "Build Back Better Act"; H.R.5801 - HELP Copays Act.
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills). Issues related to coronavirus pandemic response (HR 748: "Coronavirus Aid, Relief, and Economic Security Act").
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit and corporate tax reform implementation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills). Issues related to comprehensive corporate tax reform (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid; H.R. 5122, "To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models."
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to the Orphan Drug Tax Credit (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to rare disease and orphan disease patient access in Medicaid (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 9 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
H.R. 9 Innovation Act (all provisions)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE